(LQDA) Liquidia Technologies - Overview
Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 5.423m USD | Total Return: 312.4% in 12m
Avg Turnover: 77.1M
Qual. Beats: 0
Rev. Trend: 72.8%
Qual. Beats: 1
Warnings
P/E ratio 358.7
Share dilution 18.7% YoY
Beneish M-Score 1.00 > -1.5 - likely earnings manipulation
Altman Z'' -2.64 < 1.0 - financial distress zone
Tailwinds
Supp Ema8, Rs Leader, Idiosyncratic Leader, Tailwind, Confidence
Liquidia Corporation (LQDA) is a biopharmaceutical firm focused on developing and commercializing therapies for rare cardiopulmonary diseases, specifically pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company’s pipeline centers on treprostinil-based products, including YUTREPIA, an inhaled dry powder, and L606, a liposomal formulation currently in Phase III clinical trials.
The company utilizes its proprietary PRINT (Particle Replication in Non-wetting Templates) technology to engineer drug particles with precise control over size, shape, and chemical composition. This precision engineering is a critical differentiator in the pharmaceutical sector, as it can improve the delivery efficiency and bioavailability of inhaled medications compared to traditional milling processes.
Liquidia operates within a specialized market characterized by high barriers to entry and complex regulatory pathways for orphan drugs. Its business model relies on strategic licensing and promotion agreements with established industry players like Sandoz and GlaxoSmithKline to scale its commercial reach. For a deeper analysis of these partnerships and their impact on valuation, consider reviewing the comprehensive data on ValueRay.
- FDA final approval and commercial launch of YUTREPIA for PAH and PH-ILD
- Legal outcomes regarding treprostinil patent litigation against United Therapeutics Corporation
- Market share expansion via PRINT technology for inhaled treprostinil drug delivery
- Clinical trial progression and data readouts for L606 sustained-release formulation
- Strategic partnership execution and royalty revenue from Sandoz promotion agreement
| Net Income: 22.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA 57.47 > 1.0 |
| NWC/Revenue: 63.64% < 20% (prev 825.0%; Δ -761.4% < -1%) |
| CFO/TA 0.12 > 3% & CFO 48.0m > Net Income 22.3m |
| Net Debt (-31.0m) to EBITDA (52.0m): -0.60 < 3 |
| Current Ratio: 2.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (101.1m) vs 12m ago 18.71% < -2% |
| Gross Margin: 91.78% > 18% (prev 0.58%; Δ 9.12k% > 0.5%) |
| Asset Turnover: 91.60% > 50% (prev 6.22%; Δ 85.38% > 0%) |
| Interest Coverage Ratio: 1.94 > 6 (EBITDA TTM 52.0m / Interest Expense TTM 26.0m) |
| A: 0.46 (Total Current Assets 333.1m - Total Current Liabilities 149.7m) / Total Assets 401.5m |
| B: -1.43 (Retained Earnings -573.5m / Total Assets 401.5m) |
| C: 0.16 (EBIT TTM 50.4m / Avg Total Assets 314.5m) |
| D: -1.96 (Book Value of Equity -573.4m / Total Liabilities 293.0m) |
| Altman-Z'' = -2.64 = D |
| DSRI: 2.92 (Receivables 74.2m/1.25m, Revenue 288.1m/14.1m) |
| GMI: 0.63 (GM 91.78% / 58.08%) |
| AQI: 0.65 (AQ_t 0.11 / AQ_t-1 0.17) |
| SGI: 20.37 (Revenue 288.1m / 14.1m) |
| TATA: -0.06 (NI 22.3m - CFO 48.0m) / TA 401.5m) |
| Beneish M = 11.83 (Cap -4..+1) = D |
As of May 30, 2026, the stock is trading at USD 61.86 with a total of 1,242,517 shares traded.
Over the past week, the price has changed by -0.18%,
over one month by +62.15%,
over three months by +99.42% and
over the past year by +312.40%.
Liquidia Technologies has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy LQDA.
- StrongBuy: 6
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 65.1 | 5.3% |
P/E Trailing = 358.7059
P/E Forward = 29.4118
P/S = 18.825
P/B = 49.9437
Revenue TTM = 288.1m USD
EBIT TTM = 50.4m USD
EBITDA TTM = 52.0m USD
Long Term Debt = 127.6m USD (from longTermDebt, last quarter)
Short Term Debt = 51.0m USD (from shortTermDebt, last quarter)
Debt = 191.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 6.96m
Net Debt = -31.0m USD (calculated: Debt 191.8m - CCE 222.8m)
Enterprise Value = 5.39b USD (5.42b + Debt 191.8m - CCE 222.8m)
Interest Coverage Ratio = 1.94 (Ebit TTM 50.4m / Interest Expense TTM 26.0m)
EV/FCF = 131.0x (Enterprise Value 5.39b / FCF TTM 41.1m)
FCF Yield = 0.76% (FCF TTM 41.1m / Enterprise Value 5.39b)
FCF Margin = 14.28% (FCF TTM 41.1m / Revenue TTM 288.1m)
Net Margin = 7.74% (Net Income TTM 22.3m / Revenue TTM 288.1m)
Gross Margin = 91.78% ((Revenue TTM 288.1m - Cost of Revenue TTM 23.7m) / Revenue TTM)
Gross Margin QoQ = 90.86% (prev 92.33%)
Tobins Q-Ratio = 13.43 (Enterprise Value 5.39b / Total Assets 401.5m)
Interest Expense / Debt = 13.55% (Interest Expense 26.0m / Debt 191.8m)
Taxrate = 6.90% (3.92m / 56.8m)
NOPAT = 47.0m (EBIT 50.4m * (1 - 6.90%))
Current Ratio = 2.22 (Total Current Assets 333.1m / Total Current Liabilities 149.7m)
Debt / Equity = 1.77 (Debt 191.8m / totalStockholderEquity, last quarter 108.6m)
Debt / EBITDA = -0.60 (Net Debt -31.0m / EBITDA 52.0m)
Debt / FCF = -0.75 (Net Debt -31.0m / FCF TTM 41.1m)
Total Stockholder Equity = 47.6m (last 4 quarters mean from totalStockholderEquity)
RoA = 7.09% (Net Income 22.3m / Total Assets 401.5m)
RoE = 3.59% (Net Income TTM 22.3m / Total Stockholder Equity 621.1m)
RoCE = 6.74% (EBIT 50.4m / Capital Employed (Equity 621.1m + L.T.Debt 127.6m))
RoIC = 15.51% (NOPAT 47.0m / Invested Capital 302.8m)
WACC = 10.43% (E(5.42b)/V(5.61b) * Re(10.35%) + D(191.8m)/V(5.61b) * Rd(13.55%) * (1-Tc(0.07)))
Discount Rate = 10.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 21.14%
[DCF] Terminal Value 68.51% ; FCFF base≈41.1m ; Y1≈41.3m ; Y5≈43.8m
[DCF] Fair Price = 6.01 (EV 503.0m - Net Debt -31.0m = Equity 534.0m / Shares 88.9m; r=10.43% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.69 | # QB: 0
Revenue Correlation: 72.84 | Revenue CAGR: 132.6% | SUE: 1.04 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.84 | Chg30d=+57.74% | Revisions=+14% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.97 | Chg30d=+32.33% | Revisions=+14% | Analysts=5
EPS current Year (2026-12-31): EPS=3.48 | Chg30d=+34.99% | Revisions=+14% | GrowthEPS=+535.0% | GrowthRev=+357.9%
EPS next Year (2027-12-31): EPS=5.57 | Chg30d=+6.38% | Revisions=+14% | GrowthEPS=+60.1% | GrowthRev=+61.6%
[Analyst] Revisions Ratio: +14%